Specialised wastewater treatment for pharmaceutical production. Handle API residues, solvents, high COD, and stringent discharge requirements with proven processes.
Specialised solutions for API manufacturing, formulation, R&D and biopharma facilities
Pharmaceutical manufacturing generates complex wastewater containing active pharmaceutical ingredients (APIs), solvents, high organic loads, and variable pH. Regulatory requirements mandate near-complete removal of APIs to prevent environmental contamination and antimicrobial resistance. Reynolds & Bauhm provides specialised treatment trains combining advanced oxidation, biological treatment, and membrane separation to achieve stringent discharge standards including FDA 21 CFR, EMA, and WHO guidelines.
Our pharmaceutical wastewater solutions integrate multiple treatment stages tailored to your effluent profile. For high-strength API streams, we deploy AOP (Advanced Oxidation Processes) using ozone/UV or Fenton reactions to break down recalcitrant compounds. Biological treatment with MBBR or MBR follows for bulk COD removal. Tertiary treatment with activated carbon or reverse osmosis provides the final polish for direct discharge or reuse applications.
Primary production of active pharmaceutical ingredients including fermentation, chemical synthesis, and extraction processes with high-strength organic wastewater.
Tablet coating, liquid filling, and packaging operations generating cleaning-in-place (CIP) wastewater with surfactants and product residues.
Research and development facilities with varied small-batch effluents requiring flexible, robust treatment capable of handling shock loads.
Biological manufacturing including cell culture, protein purification, and monoclonal antibody production with specialised effluent characteristics.
Compliance with current Good Manufacturing Practice requirements for finished pharmaceuticals including wastewater management and environmental controls.
European Medicines Agency environmental risk assessment requirements for human pharmaceuticals and their metabolites in wastewater.
World Health Organization Good Manufacturing Practices for pharmaceutical products including water quality and waste management protocols.
Priority substances framework including diclofenac and other watch-list pharmaceuticals requiring treatment verification.
A leading European API manufacturer faced escalating discharge volumes and regulatory pressure to remove trace APIs from effluent. Reynolds & Bauhm designed a treatment train combining AOP pre-treatment (ozone/UV) with MBBR biological treatment and GAC polishing. The system achieved 99.7% API removal across 12 target compounds, reduced COD from 15,000 mg/L to <125 mg/L, and enabled water reuse for cooling tower makeup. Project Benefits was achieved within 18 months through discharge volume benefits.
Our engineers will analyse your pharmaceutical effluent, recommend the optimal treatment train, and provide a detailed compliance assessment with technical and operational analysis.
Filter press dewatering equipment for mineral slurries, lime sludge, and landfill-bound cake.
View PageProcess equipment and instrumentation for critical water treatment processes.
View PageDiscuss your specific requirements with our technical team and receive a tailored proposal for your project.
Contact UsMBR + advanced oxidation solution achieving full API removal and GMP-compliant effluent for a bulk drug manufacturer.
Read case study →How pharmaceutical manufacturers can achieve net-zero water ambitions through reuse, energy recovery, and circular economy design.
View sustainability guide →Common questions on RO membranes, rejection rates, and pharmaceutical-grade water production.
Read FAQs →Our expertise spans multiple industries with sector-specific water treatment solutions.